Dec 6th, 2018 - Six new Clinical Practice Guidelines on Venous Thromboembolism have just been announced.
Dec 6th, 2018 - The society continues to grow its international influence and help improve hematologic care around the globe.
Dec 6th, 2018 - A look ahead to 2019, with ASH President-Elect, Dr. Roy Silverstein
Dec 6th, 2018 - Each year, ASH’s Choosing Wisely Champions Initiative recognizes three practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.
Dec 6th, 2018 - The plenary scientific session is a highlight of the annual meeting, where attendees hear presentations of the 6 highest caliber scientific abstracts.
Dec 6th, 2018 - A preview of the Late Breaking Abstracts and The Best of ASH.
Dec 6th, 2018 - A look at some of the dynamic scientific panels and presentations including the new frontier of glycobiology and new insights into neonatal hematology
Dec 6th, 2018 - Scientific spotlight sessions at the ASH annual meeting provided an in-depth review of specific scientific topics.
Dec 6th, 2018 - ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease
Dec 4th, 2018 - Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients
Dec 4th, 2018 - Tait D. Shanafelt, MD, of Stanford University, discusses phase III study findings on ibrutinib-based therapy vs standard fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy
Dec 4th, 2018 - Shaji K. Kumar, MD, of the Mayo Clinic, discusses phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma
Dec 3rd, 2018 - Five new ASH guidelines for sickle cell disease are on the way, likely early in 2019.
Dec 3rd, 2018 - Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Merav Bar, MD, of the Fred Hutchinson Cancer Research Center, discuss study findings on the long-term effects in people with relapsed or refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia
Dec 3rd, 2018 - Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings on brentuximab vedotin and CHP vs CHOP in the front-line treatment of patients with CD30-positive
Dec 3rd, 2018 - Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma
Dec 3rd, 2018 - Norman E. Sharpless, MD, Director of the National Cancer Institute, discusses his vision for the NCI in four key areas––big data, clinical trials, workforce development, and basic science
Dec 3rd, 2018 - John P. Leonard, MD, of Weill Cornell Medicine/Cornell University, discusses phase III findings on lenalidomide plus rituximab vs rituximab plus placebo for people with relapsed or refractory indolent non-Hodgkin lymphoma
Dec 3rd, 2018 - Paul Richardson, MD, of Harvard University, discusses updated results and the first report on progression-free survival for melflufen therapy administered to people with multiple myeloma that is refractory to daratumumab and/or pomalidomide (Abstract 600).
Dec 3rd, 2018 - Francesca M. Gay, MD, of GIMEMA, European Myeloma Network, discusses study findings on the use of carfilzomib in induction combination regimens with autologous transplantation